Apolipoprotein E genotype as a most significant predictor of lipid response at lipid-lowering therapy: Mechanistic and clinical studies

被引:21
作者
Dergunov, A. D. [1 ]
机构
[1] Natl Res Ctr Prevent Med, Moscow 101990, Russia
基金
俄罗斯基础研究基金会;
关键词
Apolipoprotein E; Triglyceride; Lipid-lowering therapy; CHOLESTERYL ESTER TRANSFER; HIGH-DENSITY-LIPOPROTEIN; VERY-LOW-DENSITY; A-I METABOLISM; HEPATIC LIPASE; TRANSFER PROTEIN; E POLYMORPHISM; CAPILLARY ISOTACHOPHORESIS; PLASMA-LIPOPROTEINS; ATORVASTATIN;
D O I
10.1016/j.biopha.2011.04.003
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
APOE alleles and apolipoprotein E isoforms control plasma cholesterol level on population level. Among three epsilon 2, epsilon 3, epsilon 4 alleles, epsilon 4 allele is associated with the increase in cholesterol level, risk of atherosclerosis and Alzheimer disease, while e2 allele is associated with the decrease in cholesterol level and risk of atherosclerosis. The increase in plasma triglyceride is an independent risk factor of atherosclerosis and triglyceride-high density lipoprotein coupling determines the efficiency of reverse cholesterol transport. The impairment of this coupling specifically at hypertriglyceridemia may be followed by specific lipoprotein markers. The influence of major lipid-lowering drugs on lipoprotein metabolism and association of apoE isoforms with the efficiency of therapy by statins and fibrates are summarized both at isolated and combined increase in plasma triglyceride and cholesterol. APOE polymorphism seems to be a single genetic variant with a confirmed stratification both at candidate gene and at wide genome analyses. (C) 2011 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:597 / 603
页数:7
相关论文
共 68 条
  • [1] Adkins Y, 2010, J NUTR BIOCH
  • [2] Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency
    Asztalos, BF
    Horvath, KV
    Kajinami, K
    Nartsupha, C
    Cox, CE
    Batista, M
    Schaefer, EJ
    Inazu, A
    Mabuchi, H
    [J]. JOURNAL OF LIPID RESEARCH, 2004, 45 (03) : 448 - 455
  • [3] Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes -: Effect of sex and the LIPC promoter variant
    Berk-Planken, IIL
    Hoogerbrugge, N
    Stolk, RP
    Bootsma, AH
    Jansen, H
    [J]. DIABETES CARE, 2003, 26 (02) : 427 - 432
  • [4] Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia
    Bilz, S
    Wagner, S
    Schmitz, M
    Bedynek, A
    Keller, U
    Demant, T
    [J]. JOURNAL OF LIPID RESEARCH, 2004, 45 (01) : 174 - 185
  • [5] BOERWINKLE E, 1988, AM J HUM GENET, V42, P104
  • [6] Sterol-regulatory-element binding protein inhibits upstream stimulatory factor-stimulated hepatic lipase gene expression
    Botma, GJ
    van Deursen, D
    Vieira, D
    van Hoek, M
    Jansen, H
    Verhoeven, AJM
    [J]. ATHEROSCLEROSIS, 2005, 179 (01) : 61 - 67
  • [7] Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs
    Briand, F
    Magot, T
    Krempf, M
    Nguyen, P
    Ouguerram, K
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2006, 36 (04) : 224 - 230
  • [8] Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients
    Brisson, D
    Ledoux, K
    Bossé, Y
    St-Pierre, J
    Julien, P
    Perron, P
    Hudson, TJ
    Vohl, MC
    Gaudet, D
    [J]. PHARMACOGENETICS, 2002, 12 (04): : 313 - 320
  • [9] Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion
    Brousseau, ME
    Diffenderfer, MR
    Millar, JS
    Nartsupha, C
    Asztalos, BF
    Welty, FK
    Wolfe, ML
    Rudling, M
    Björkhem, I
    Angelin, B
    Mancuso, JP
    Digenio, AG
    Rader, DJ
    Schaefer, EJ
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (05) : 1057 - 1064
  • [10] Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
    Brousseau, ME
    Schaefer, EJ
    Wolfe, ML
    Bloedon, LT
    Digenio, AG
    Clark, RW
    Mancuso, JP
    Rader, DJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) : 1505 - 1515